503A vs 503B
Two compounding-pharmacy categories exist under U.S. federal law. A 503A pharmacy compounds patient-specific prescriptions, dispensed against a valid physician order, for a named individual. A 503B outsourcing facility manufactures in bulk under cGMP and can supply hospitals and clinics without a patient-specific prescription.
Nexphoria operates exclusively through 503A pharmacy partners. Every order is a patient-specific prescription written by a licensed clinician following a real evaluation. This is not a workaround. It is the lawful path.
FDA enforcement discretion
Some peptides — semaglutide, tirzepatide — were placed on the FDA shortage list during 2023-2024, which allowed 503A pharmacies to compound them. As shortages resolve, that latitude narrows. Reputable telehealth providers track shortage status weekly and adjust formulary accordingly.
We do not compound peptides that have lost shortage status unless they have a legitimate compounding pathway (e.g., personalized dosing, allergy-driven excipient swap).
What 'research-only' actually means
Vials labeled 'for research only' or 'not for human consumption' are exactly that. The label is not a wink. It is the legal posture of a chemical supplier who has not validated identity, purity, sterility, or endotoxin load to clinical standards.
Research-grade peptides should not be self-administered. Period.
Share
References
- [1]U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. Updated 2024. Link